55.49

1.28% 0.70

After Hours: 54.52 -0.97 -1.75%

Bridgebio Pharma Inc (BBIO)

Overview News Price History Option Chain Financials Why BBIO Down? Discussions Forecast

Bridgebio Pharma Inc stock is traded at $55.49, with a volume of 3.26M. It is up +1.28% in the last 24 hours and up +4.78% over the past month. BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.

Previous Close:

$54.79

Open:

$54.83

24h Volume:

3.26M

Relative Volume:

1.35

Market Cap:

$10.61B

Revenue:

$217.77M

Net Income/Loss:

$-438.86M

P/E Ratio:

-23.02

EPS:

-2.41

Net Cash Flow:

$-456.33M

1W Performance:

+4.98%

1M Performance:

+4.78%

6M Performance:

+71.74%

1Y Performance:

+122.32%

1-Day Range:

$54.66

$55.94

1-Week Range:

$52.97

$55.94

52-Week Range:

$21.72

$55.94

Bridgebio Pharma Inc Stock (BBIO) Company Profile

Name

Bridgebio Pharma Inc

Sector

Healthcare (1141)

Industry

Biotechnology (637)

Phone

(650) 391-9740

Address

3160 PORTER DR., PALO ALTO, CA

Employee

730

Twitter

Next Earnings Date

2024-10-31

Latest SEC Filings

BBIO's Discussions on Twitter

Compare BBIO with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
BBIO Bridgebio Pharma Inc	55.49	10.47B	217.77M	-438.86M	-456.33M	-2.41
VRTX Vertex Pharmaceuticals Inc	407.79	106.37B	11.39B	3.64B	3.50B	13.99
ALNY Alnylam Pharmaceuticals Inc	460.46	59.90B	2.46B	-319.09M	-52.09M	-2.4669
REGN Regeneron Pharmaceuticals Inc	564.63	60.40B	14.21B	4.46B	3.56B	39.69
ARGX Argen X Se Adr	796.92	49.56B	3.06B	1.28B	447.35M	19.67
ONC Beone Medicines Ltd Adr	320.10	36.88B	4.56B	-176.77M	225.30M	-1.7177

Bridgebio Pharma Inc Stock (BBIO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-30-25	Resumed	Raymond James	Outperform
Jul-21-25	Initiated	Truist	Buy
Jul-14-25	Initiated	Jefferies	Buy
Jul-09-25	Upgrade	Oppenheimer	Perform → Outperform
Jun-17-25	Initiated	Wolfe Research	Outperform
Mar-31-25	Initiated	Redburn Atlantic	Buy
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Oct-03-24	Initiated	Oppenheimer	Perform
Sep-04-24	Initiated	Piper Sandler	Overweight
Mar-21-24	Resumed	Raymond James	Outperform
Jan-31-24	Initiated	BMO Capital Markets	Market Perform
Dec-08-23	Initiated	Wells Fargo	Overweight
Nov-07-23	Initiated	Citigroup	Buy
Oct-24-23	Initiated	Cantor Fitzgerald	Overweight
Jul-18-23	Downgrade	Jefferies	Buy → Hold
Apr-19-23	Initiated	Evercore ISI	Outperform
Feb-06-23	Initiated	Cowen	Outperform
Dec-27-21	Reiterated	Mizuho	Buy
Dec-27-21	Reiterated	SVB Leerink	Outperform
Sep-10-21	Upgrade	BofA Securities	Neutral → Buy
May-21-21	Initiated	UBS	Buy
Mar-22-21	Reiterated	Goldman	Buy
Feb-22-21	Resumed	JP Morgan	Overweight
Feb-09-21	Resumed	Goldman	Buy
Jan-11-21	Reiterated	H.C. Wainwright	Buy
Dec-10-20	Reiterated	H.C. Wainwright	Buy
Jun-25-20	Initiated	BofA/Merrill	Neutral
May-19-20	Initiated	BTIG Research	Buy
Apr-13-20	Initiated	H.C. Wainwright	Buy
Feb-19-20	Initiated	Mizuho	Buy
Jul-26-19	Initiated	Raymond James	Outperform
Jul-22-19	Initiated	BMO Capital Markets	Outperform
Jul-22-19	Initiated	Goldman	Buy
Jul-22-19	Initiated	JP Morgan	Overweight
Jul-22-19	Initiated	Jefferies	Buy
Jul-22-19	Initiated	Piper Jaffray	Overweight
Jul-22-19	Initiated	SVB Leerink	Outperform

View All

Bridgebio Pharma Inc Stock (BBIO) Latest News

Oct 12, 2025

Sentiment analysis tools applied to BridgeBio Pharma Inc.Weekly Trade Summary & Safe Entry Momentum Tips - newser.com

Oct 12, 2025

Oak Ridge Investments LLC Purchases New Holdings in BridgeBio Pharma, Inc. $BBIO - MarketBeat

Oct 12, 2025

Published on: 2025-10-12 03:32:49 - newser.com

Oct 12, 2025

Oct 11, 2025

BridgeBio Pharma (NASDAQ:BBIO) CEO Neil Kumar Sells 40,000 Shares - MarketBeat

Oct 11, 2025

Oct 10, 2025

Using flow based indicators on BridgeBio Pharma Inc.2025 Analyst Calls & Consistent Profit Trading Strategies - newser.com

Oct 10, 2025

Why BridgeBio Pharma Inc. (2CL) stock could outperform next yearJuly 2025 Breakouts & AI Based Trade Execution Alerts - newser.com

Oct 10, 2025

Will BridgeBio Pharma Inc. bounce back from current supportWeekly Risk Summary & Safe Entry Momentum Stock Tips - newser.com

Oct 10, 2025

Oct 09, 2025

BridgeBio Pharma (NASDAQ:BBIO) Given Sell (D-) Rating at Weiss Ratings - MarketBeat

Oct 09, 2025

BridgeBio Pharma Hits New 52-Week High of $55.33, Up 98.71% - Markets Mojo

Oct 09, 2025

Using economic indicators to assess BridgeBio Pharma Inc. potentialJuly 2025 Intraday Action & Daily Chart Pattern Signals - newser.com

Oct 09, 2025

Leading vs lagging indicators on BridgeBio Pharma Inc. performance2025 Momentum Check & Free Fast Entry Momentum Trade Alerts - newser.com

Oct 09, 2025

Real time breakdown of BridgeBio Pharma Inc. stock performanceIPO Watch & Risk Managed Investment Signals - newser.com

Oct 09, 2025

Will breakout in BridgeBio Pharma Inc. lead to full recoveryJuly 2025 Intraday Action & Growth Focused Entry Point Reports - newser.com

Oct 09, 2025

Oct 08, 2025

BridgeBio Pharma, Inc. Experiences Revision in Stock Evaluation Amid Strong Market Performance - Markets Mojo

Oct 08, 2025

BridgeBio Pharma Hits New 52-Week High of $54.64, Up 96.23% - Markets Mojo

Oct 08, 2025

Oct 06, 2025

BridgeBio Pharma (NASDAQ:BBIO) Sets New 12-Month HighHere's What Happened - MarketBeat

Oct 06, 2025

BridgeBio Pharma stock hits 52-week high at $54.61 By Investing.com - Investing.com South Africa

Oct 06, 2025

BridgeBio Pharma stock hits 52-week high at $54.61 - Investing.com

Oct 06, 2025

Analyzing drawdowns of BridgeBio Pharma Inc. with statistical toolsJuly 2025 Decliners & Fast Gaining Stock Strategy Reports - newser.com

Oct 06, 2025

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(4) - MarketScreener

Oct 06, 2025

How buybacks impact BridgeBio Pharma Inc. stock valueGap Up & Growth Focused Stock Reports - newser.com

Oct 06, 2025

PFG Investments LLC Takes Position in BridgeBio Pharma, Inc. $BBIO - MarketBeat

Oct 06, 2025

What MACD and RSI say about BridgeBio Pharma Inc.Weekly Market Outlook & Target Return Focused Stock Picks - newser.com

Oct 06, 2025

Oct 05, 2025

Pattern recognition hints at BridgeBio Pharma Inc. upsideJuly 2025 EndofMonth & Pattern Based Trade Signal System - newser.com

Oct 05, 2025

Oct 04, 2025

BridgeBio Pharma (BBIO) Is Up 5.6% After Acoramidis Shows Broad ATTR-CM Benefit in Phase 3 Data - Yahoo

Oct 04, 2025

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Oct 04, 2025

Oct 03, 2025

BridgeBio Pharma reports inducement grants under Nasdaq Listing Rule - MarketScreener

Oct 03, 2025

23,884 RSUs: BridgeBio Grants Inducement Shares with Quarterly Vesting Starting Nov. 16, 2026 - Stock Titan

Oct 03, 2025

What earnings revisions data tells us about BridgeBio Pharma Inc.2025 Geopolitical Influence & Daily Risk Controlled Trade Plans - newser.com

Oct 03, 2025

How big funds are accumulating BridgeBio Pharma Inc. (2CL) stockJuly 2025 Summary & Low Drawdown Trading Strategies - newser.com

Oct 03, 2025

Oct 02, 2025

UBS Reaffirms Buy on BridgeBio (BBIO) With Optimism Around Attruby Launch - Yahoo Finance

Oct 02, 2025